Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring Amplifications.
作者信息
Dumbrava Ecaterina Ileana, Alfattal Rasha, Miller Vincent A, Tsimberidou Apostolia Maria
机构信息
Ecaterina Ileana Dumbrava, Rasha Alfattal, and Apostolia Maria Tsimberidou, The University of Texas MD Anderson Cancer Center, Houston, TX; and Vincent A. Miller, Foundation Medicine, Cambridge, MA.
出版信息
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00100. Epub 2018 Aug 31.
Abstract
摘要
相似文献
1
Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring Amplifications.
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00100. Epub 2018 Aug 31.
2
Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.
Head Neck. 2016 Apr;38 Suppl 1(Suppl 1):E1646-52. doi: 10.1002/hed.24292. Epub 2016 Feb 5.
3
Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 May;93(5):573-9. doi: 10.1067/moe.2002.124461.
4
Immunohistochemical study of fibroblast growth factor-2 (FGF-2) and fibroblast growth factor receptor (FGF-R) in experimental squamous cell carcinoma of rat submandibular gland.
Oral Oncol. 1999 Jan;35(1):98-104. doi: 10.1016/s1368-8375(98)00067-0.
5
Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11.
6
Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma.
Oral Oncol. 2013 Aug;49(8):761-70. doi: 10.1016/j.oraloncology.2013.03.452. Epub 2013 Apr 24.
7
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Cancer Metastasis Rev. 2015 Sep;34(3):479-96. doi: 10.1007/s10555-015-9579-8.
8
Eldecalcitol (ED-71), an analog of 1α,25(OH)D, inhibits the growth of squamous cell carcinoma (SCC) cells in vitro and in vivo by down-regulating expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) and FGF-2.
In Vitro Cell Dev Biol Anim. 2017 Oct;53(9):810-817. doi: 10.1007/s11626-017-0183-9. Epub 2017 Jul 14.
9
Combination antiangiogenic therapy and radiation in head and neck cancers.
Oral Oncol. 2014 Jan;50(1):19-26. doi: 10.1016/j.oraloncology.2013.10.003. Epub 2013 Oct 23.
10
Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells.
Am J Surg. 1997 Nov;174(5):540-4. doi: 10.1016/s0002-9610(97)00169-4.
引用本文的文献
1
FGFR1 Signaling Facilitates Obesity-Driven Pulmonary Outgrowth in Metastatic Breast Cancer.
Mol Cancer Res. 2024 Mar 1;22(3):254-267. doi: 10.1158/1541-7786.MCR-23-0955.
2
First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
JAMA Netw Open. 2023 Jul 3;6(7):e2323336. doi: 10.1001/jamanetworkopen.2023.23336.
3
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer.
Cancer J. 2022;28(5):354-362. doi: 10.1097/PPO.0000000000000615.
4
Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
Int J Mol Sci. 2022 Jul 17;23(14):7889. doi: 10.3390/ijms23147889.
5
A Novel CXCR4-Targeted Diphtheria Toxin Nanoparticle Inhibits Invasion and Metastatic Dissemination in a Head and Neck Squamous Cell Carcinoma Mouse Model.
Pharmaceutics. 2022 Apr 18;14(4):887. doi: 10.3390/pharmaceutics14040887.
6
Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Clin Epigenetics. 2021 Dec 21;13(1):228. doi: 10.1186/s13148-021-01212-4.
7
A cyclic peptide retards the proliferation of DU145 prostate cancer cells in vitro and in vivo through inhibition of FGFR2.
MedComm (2020). 2020 Dec 14;1(3):362-375. doi: 10.1002/mco2.48. eCollection 2020 Dec.
8
A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity.
Science. 2021 Oct;374(6563):eabf2911. doi: 10.1126/science.abf2911. Epub 2021 Oct 1.
9
Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma.
PLoS One. 2021 Feb 24;16(2):e0247498. doi: 10.1371/journal.pone.0247498. eCollection 2021.
10
Landscape of / Alterations in 12,372 Chinese Cancer Patients.
J Cancer. 2020 Sep 23;11(22):6695-6699. doi: 10.7150/jca.49269. eCollection 2020.
本文引用的文献
1
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification.
Ann Oncol. 2017 Jun 1;28(6):1316-1324. doi: 10.1093/annonc/mdx107.
2
A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Clin Cancer Res. 2017 Sep 15;23(18):5366-5373. doi: 10.1158/1078-0432.CCR-17-0645. Epub 2017 Jun 14.
3
FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Crit Rev Oncol Hematol. 2017 May;113:256-267. doi: 10.1016/j.critrevonc.2017.02.018. Epub 2017 Mar 23.
4
Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study.
Invest New Drugs. 2017 Aug;35(4):451-462. doi: 10.1007/s10637-016-0416-x. Epub 2017 Jan 10.
5
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.
Oncotarget. 2017 Feb 28;8(9):16052-16074. doi: 10.18632/oncotarget.14109.
6
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
J Clin Oncol. 2017 Jan 10;35(2):157-165. doi: 10.1200/JCO.2016.67.2048. Epub 2016 Nov 21.
7
FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies.
Cell Death Discov. 2015 Nov 23;1:15049. doi: 10.1038/cddiscovery.2015.49. eCollection 2015.
8
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Clin Cancer Res. 2016 Aug 1;22(15):3884-93. doi: 10.1158/1078-0432.CCR-15-1874. Epub 2016 Mar 2.
9
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mol Carcinog. 2017 Jan;56(1):106-117. doi: 10.1002/mc.22476. Epub 2016 Feb 24.
10
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Semin Oncol. 2015 Dec;42(6):801-19. doi: 10.1053/j.seminoncol.2015.09.027. Epub 2015 Sep 24.
Zotero 插件